<DOC>
	<DOCNO>NCT01691053</DOCNO>
	<brief_summary>End stage renal disease ( ESRD ) patient exhibit extraordinarily high annual mortality . Cardiovascular ( CV ) cause account almost half all-cause mortality . Increased leave ventricular mass ( LVM ) common find ESRD patient dialysis independent predictor survival . Yet , date establish medical treatment reduce CV morbidity mortality ESRD patient hemodialysis . Blockade aldosterone action mean mineralocorticoid receptor antagonist ( MRA ) provide cardioprotection improve outcome heart failure patient . Furthermore , MRA spironolactone recently show reduce LVM patient mild-to-moderate chronic kidney disease ( CKD ) . The investigator hypothesize spironolactone treatment cardioprotective reduce LVM ESRD patient dialysis .</brief_summary>
	<brief_title>Mineralocorticoid Receptor Antagonists End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>Age &gt; 18 year Hemodialysis treatment least 3 month At least 3 dialysis session per week Written inform consent Contraindications cardiac magnet resonance imaging ( CMR ) Mineralocorticoid receptor antagonist treatment within last 6 month Estimated life expectancy &lt; 12 month judge nephrologist History hyperkalemia , define predialysis potassium &gt; 6.5 mmol/l occur â‰¥ 3 time within last 3 month prior enrolment . High risk develop hyperkalemia define predialysis potassium &gt; 6.0 mmol/l Hypotension ( systolic blood pressure &lt; 100 mmHg ) Planned kidney transplantation ( live donor ) within prospect study duration Any acute illness within last 4 week preclude study participation judge nephrologist Nonamenorrheic woman child bear potential without reliable contraception , pregnancy/lactation Allergy/hypersensitivity spironolactone Noncompliance suspect demonstrate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>End stage renal disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Left ventricular hypertrophy</keyword>
</DOC>